Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Desvenlafaxine Sustained-Release · 5 trials · 1 indication
Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.
Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Mean change from baseline was adjusted for the baseline total score, age group and gender.
Time to relapse analyzed using log-rank test; defined as Hamilton Psychiatric Scale for Depression-17 item score ≥16 at any time during DB phase, discontinuation for unsatisfactory response or efficacy (need for additional or alternate treatment for depression, investigator decision to remove participant for efficacy reasons, or failure to return if investigator determined related to efficacy), hospitalization for depression, suicide attempt, or suicide. Participants who relapsed after DB day 185 or completed DB therapy without relapse were considered as censored on DB day 185 (study day 325).
HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.
HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4) with 0=none/absent and 4=most severe, for a maximum total score of 50. Higher scores indicate greater severity. FOT evaluation is defined as the last "on-therapy" evaluation, regardless of the number of days on therapy. Analysis on Observed cases (non-missing data) and Last observation carried forward (LOCF); LOCF method of imputation for any missing value at any visit.
Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship. An AE resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be an SAE: death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly.
| Arm | Type | Description |
|---|---|---|
| DVS SR | EXPERIMENTAL | - |
| Fluoxetine | OTHER | Active control for assay sensitivity |
| Placebo | EXPERIMENTAL | - |
| Experimental Arm 1 - high dose | EXPERIMENTAL | - |
| Experimental Arm 2 - low dose | EXPERIMENTAL | - |
| Placebo Arm | PLACEBO_COMPARATOR | - |
| Desvenlafaxine succinate sustained release 50 mg | EXPERIMENTAL | - |
| Desvenlafaxine succinate sustained release 10 mg | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | DVS SR |
| Name | Type | Description |
|---|---|---|
| desvenlafaxine succinate sustained release | DRUG | Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets. |
| fluoxetine | DRUG | Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules |
| placebo | DRUG | Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules |
| Desvenlafaxine Succinate Sustained-Release | DRUG | Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit. |
| Desvenlafaxine succinate sustained release 50 mg | DRUG | 50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm. |
| Desvenlafaxine succinate sustained release 25 mg | DRUG | 25 mg tablet for taper, once daily for 1 week |
| Desvenlafaxine Succinate Sustained-Release 10mg | DRUG | 10 mg tablet, once daily dosing for 8 weeks |
| Desvenlafaxine Succinate Sustained-Release 50 mg | DRUG | 50 mg tablet, once daily dosing for 8 weeks |
| desvenlafaxine succinate sustained release tablets | DRUG | 25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet. |
Inclusion Criteria: * Age \>=7 and \<18 years of age * Primary diagnosis of major depressive disorder (MDD) * CDRS-R score \>40 Exclusion Criteria: * History of suicidal behaviour, or requires precaution against suicide * Not in generally healthy medical condition * History of psychosis or bipola...
Top 20 of 29 competitors
Desvenlafaxine Sustained Release is an investigational small molecule being studied for major depressive disorder, vasomotor symptoms, and fibromyalgia. It is developed by Pfizer, Inc. (PFE). The drug is in Phase 2 clinical development and is not approved by the FDA.
Desvenlafaxine Sustained Release is a small molecule, but its specific molecular target has not been disclosed in the available information. It is being studied for its effects on depression, vasomotor symptoms, and fibromyalgia, though the mechanism of action is not detailed.
Desvenlafaxine Sustained Release is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The drug is currently in Phase 2 clinical development for major depressive disorder, vasomotor symptoms, and fibromyalgia.
Desvenlafaxine Sustained Release is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The development program includes completed Phase 1, Phase 2, and Phase 3 trials across various indications, but the current stage is Phase 2.
Desvenlafaxine Sustained Release has completed five clinical trials, including NCT00424892 in fibromyalgia, NCT00863798 in major depressive disorder, NCT01190514 a bioequivalence study, and NCT01371734 in children and adolescents with major depressive disorder. All trials are completed, with no active trials ongoing.
Desvenlafaxine Sustained Release is also known as desvenlafaxine succinate sustained release, often abbreviated as DVS SR. Clinical trials such as NCT01190514 refer to the drug as desvenlafaxine succinate sustained release, confirming that these names describe the same investigational compound.